374 related articles for article (PubMed ID: 8215278)
1. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
2. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Appelbaum PC; Spangler SK; Jacobs MR
J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
[TBL] [Abstract][Full Text] [Related]
4. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
[TBL] [Abstract][Full Text] [Related]
5. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
[TBL] [Abstract][Full Text] [Related]
6. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
[TBL] [Abstract][Full Text] [Related]
10. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
12. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
[TBL] [Abstract][Full Text] [Related]
13. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
14. [In vitro effect of piperacillin, amoxicillin, cefoxitin and metronidazole against obligate anaerobic bacteria].
Derriennic M; Reynaud A; Launay C; Courtieu AL
Presse Med; 1986 Dec; 15(46):2279-81. PubMed ID: 2949268
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
16. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
Watt B; Naden M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital.
Tan TY; Ng LS; Kwang LL; Rao S; Eng LC
Anaerobe; 2017 Feb; 43():69-74. PubMed ID: 27890724
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
19. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Credito KL; Ednie LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2027-31. PubMed ID: 10428930
[TBL] [Abstract][Full Text] [Related]
20. [Sensitivity of strict anaerobic bacteria to metronidazole, cefoxitin, and clindamycin].
Dubreuil L; Derriennic M; Reynaud A; Devos J; Romond C; Courtieu A
Pathol Biol (Paris); 1985 Nov; 33(9):899-903. PubMed ID: 3909082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]